Application 218881

Type: NDA
Sponsor: ELI LILLY AND CO

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	INLURIYO	IMLUNESTRANT TOSYLATE	TABLET;ORAL	EQ 200MG BASE	Yes	Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N218881-001	INLURIYO	IMLUNESTRANT TOSYLATE	EQ 200MG BASE	TABLET / ORAL		RLD, RS	2025-09-25

Orange Book patents#

Current patent rows page 1 of 1 · 2 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16
N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16

Orange Book exclusivity#

Current exclusivity rows page 1 of 1 · 1 matching rows.

Application-product, Exclusivity code, Expiration table
Application-product	Exclusivity code	Expiration
N218881-001	NCE	2030-09-25

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N218881-001	INLURIYO	EQ 200MG BASE	TABLET / ORAL	RLD, RS	2025-09-25	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218881-001	INLURIYO	EQ 200MG BASE	TABLET / ORAL	RLD, RS	2025-09-25	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N218881-001	INLURIYO	EQ 200MG BASE	TABLET / ORAL	RLD, RS	2025-09-25	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218881-001	INLURIYO	EQ 200MG BASE	TABLET / ORAL	RLD, RS	2025-09-25	`31067a03dcf5…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218881-001	INLURIYO	EQ 200MG BASE	TABLET / ORAL	RLD, RS	2025-09-25	`a50c72e98297…`

Observed Orange Book patent history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-09-14 22:38:34	2026-08	N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`31067a03dcf5…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218881-001	10654866	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218881-001	11117902	2039-07-11	U-4278	Drug substance, Drug product	2025-10-16	`a50c72e98297…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2026-09-14 22:38:34	2026-08	N218881-001	NCE	2030-09-25	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N218881-001	NCE	2030-09-25	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N218881-001	NCE	2030-09-25	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N218881-001	NCE	2030-09-25	`31067a03dcf5…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N218881-001	NCE	2030-09-25	`a50c72e98297…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Inluriyo	IMLUNESTRANT	Eli Lilly and Company	5bc172e4-e8a2-441a-be52-279a7f890196	2026-06-04	Warnings, Adverse reactions	Exact identifier application applno (NDA): 218881 application number: NDA218881

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Documents#

Document, Submission type, Date table
Document	Submission type	Date
83915	ORIG	2025-10-27
83543	ORIG	2025-09-26
83533	ORIG	2025-09-26